Tags

Type your tag names separated by a space and hit enter

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Abstract

BACKGROUND

In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children.

METHODS

Children aged 15-120 months vaccinated one year before with the ASO3-adjuvanted monovalent pandemic vaccine were tested for the presence of antibody against 2010-2011 TIV components (A/California/7/2009(H1N1), A/Wisconsin/15/2009 (H3N2 A/Perth/16/2009-like) and B/Brisbane/60/2008) before and 21-28 days after each dose of 2010-2011 TIV. Hemagglutination-inhibition (HAI) assay was used. Children received one or two doses of 2010-2011 TIV at 21-28 days interval in relation with their previous immunization status.

RESULTS

The results of 128 children were included in the ATP analysis. Before the 2010-2011 TIV administration, 46% of children showed sero-protection to the A/California/7/2009(H1N1) strain (HAI titre ≥40) with lower rates of sero-protection to the H3N2A/Perth/16/2009 (37%) and B/Brisbane/60/2008 (19%). After the first dose of 2010-2011 TIV, 98%, 75%, and 57% of vaccinees attained a sero-protective titre to A/California/7/2009(H1N1), A/Perth/16/2009(H3N2), and B/Brisbane/60/2008 strain, respectively. The youngest age group showed significantly lower antibody response to the influenza B component compared to the older age groups after the first dose of vaccine. Among vaccinees who received the second dose of TIV, 96% and 87% had a sero-protective titre to H3N2A/Perth/16/2009 and B/Brisbane/60/2008, respectively. The 2010-2011 TIV was well tolerated.

CONCLUSIONS

We found substantial persistence of antibody to the A/California/7/2009 strain one year after a single paediatric dose of AS03-adjuvanted pandemic vaccine and a seroprotective level of antibody to this strain in virtually all children who received one year later a single dose of the 2010-2011 TIV. In contrast, two doses of the 2010-2011 TIV were necessary to induce an adequate immune response to the A/Perth/16/2009(H3N2) and B/Brisbane/60/2008 strains in children previously naïve to seasonal vaccine.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Quebec Public Health Institute, Canada. vladimir.gilca@ssss.gouv.qc.ca

    , , , , , , , ,

    Source

    Vaccine 30:1 2011 Dec 09 pg 35-41

    MeSH

    Adjuvants, Immunologic
    Antibodies, Viral
    Child
    Child, Preschool
    Female
    Hemagglutination Inhibition Tests
    Humans
    Immunization, Secondary
    Infant
    Influenza A Virus, H1N1 Subtype
    Influenza Vaccines
    Influenza, Human
    Male
    Vaccination

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22063386

    Citation

    Gilca, Vladimir, et al. "Antibody Persistence and Response to 2010-2011 Trivalent Influenza Vaccine One Year After a Single Dose of 2009 AS03-adjuvanted Pandemic H1N1 Vaccine in Children." Vaccine, vol. 30, no. 1, 2011, pp. 35-41.
    Gilca V, De Serres G, Hamelin ME, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine. 2011;30(1):35-41.
    Gilca, V., De Serres, G., Hamelin, M. E., Boivin, G., Ouakki, M., Boulianne, N., ... Skowronski, D. (2011). Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine, 30(1), pp. 35-41. doi:10.1016/j.vaccine.2011.10.062.
    Gilca V, et al. Antibody Persistence and Response to 2010-2011 Trivalent Influenza Vaccine One Year After a Single Dose of 2009 AS03-adjuvanted Pandemic H1N1 Vaccine in Children. Vaccine. 2011 Dec 9;30(1):35-41. PubMed PMID: 22063386.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. AU - Gilca,Vladimir, AU - De Serres,Gaston, AU - Hamelin,Marie-Eve, AU - Boivin,Guy, AU - Ouakki,Manale, AU - Boulianne,Nicole, AU - Sauvageau,Chantal, AU - Dionne,Marc, AU - Gilca,Rodica, AU - Skowronski,Danuta, Y1 - 2011/11/07/ PY - 2011/04/20/received PY - 2011/10/14/revised PY - 2011/10/24/accepted PY - 2011/11/9/entrez PY - 2011/11/9/pubmed PY - 2012/3/22/medline SP - 35 EP - 41 JF - Vaccine JO - Vaccine VL - 30 IS - 1 N2 - BACKGROUND: In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children. METHODS: Children aged 15-120 months vaccinated one year before with the ASO3-adjuvanted monovalent pandemic vaccine were tested for the presence of antibody against 2010-2011 TIV components (A/California/7/2009(H1N1), A/Wisconsin/15/2009 (H3N2 A/Perth/16/2009-like) and B/Brisbane/60/2008) before and 21-28 days after each dose of 2010-2011 TIV. Hemagglutination-inhibition (HAI) assay was used. Children received one or two doses of 2010-2011 TIV at 21-28 days interval in relation with their previous immunization status. RESULTS: The results of 128 children were included in the ATP analysis. Before the 2010-2011 TIV administration, 46% of children showed sero-protection to the A/California/7/2009(H1N1) strain (HAI titre ≥40) with lower rates of sero-protection to the H3N2A/Perth/16/2009 (37%) and B/Brisbane/60/2008 (19%). After the first dose of 2010-2011 TIV, 98%, 75%, and 57% of vaccinees attained a sero-protective titre to A/California/7/2009(H1N1), A/Perth/16/2009(H3N2), and B/Brisbane/60/2008 strain, respectively. The youngest age group showed significantly lower antibody response to the influenza B component compared to the older age groups after the first dose of vaccine. Among vaccinees who received the second dose of TIV, 96% and 87% had a sero-protective titre to H3N2A/Perth/16/2009 and B/Brisbane/60/2008, respectively. The 2010-2011 TIV was well tolerated. CONCLUSIONS: We found substantial persistence of antibody to the A/California/7/2009 strain one year after a single paediatric dose of AS03-adjuvanted pandemic vaccine and a seroprotective level of antibody to this strain in virtually all children who received one year later a single dose of the 2010-2011 TIV. In contrast, two doses of the 2010-2011 TIV were necessary to induce an adequate immune response to the A/Perth/16/2009(H3N2) and B/Brisbane/60/2008 strains in children previously naïve to seasonal vaccine. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22063386/Antibody_persistence_and_response_to_2010_2011_trivalent_influenza_vaccine_one_year_after_a_single_dose_of_2009_AS03_adjuvanted_pandemic_H1N1_vaccine_in_children_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01699-9 DB - PRIME DP - Unbound Medicine ER -